Genetically Modified Micro-organism, Cell, Or Virus (e.g., Transformed, Fused, Hybrid, Etc.) Patents (Class 424/93.2)
  • Patent number: 11028131
    Abstract: The present invention provides: a mutant of adeno-associated virus (AAV) capsid protein, which contains at least one amino acid substitution in PLA2 domain when compared with the amino acid sequence for wild-type AAV capsid protein; a nucleic acid encoding the mutant; a cell containing the nucleic acid; a method for producing a recombinant AAV particle, comprising a step of culturing the cell to produce the recombinant AAV particle; a recombinant AAV particle containing the mutant; a composition containing the recombinant AAV particle; and a method for transferring a gene into a target cell, comprising a step of bringing the recombinant AAV particle into contact with the target cell.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: June 8, 2021
    Assignees: NIPPON MEDICAL SCHOOL FOUNDATION, NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY, TAKARA BIO INC.
    Inventors: Takashi Okada, Hironori Okada, Hiromi Kinoh, Tatsuji Enoki, Toshikazu Nishie, Junichi Mineno
  • Patent number: 11020465
    Abstract: Disclosed herein is a different and novel approach to cancer vaccines using a subject's own dendritic cells (DCs) and macrophages (Mphs) in combination to present cancer antigens to the immune system. Further disclosed are methods of producing monocyte-derived autologous DCs and Mphs loaded ex vivo with particular whole irradiated cancer cells which generates optimally activated immunostimulatory antigen-presenting cells (APCs) as a superior method for stimulating robust and long-lasting immunity to a particular cancer in vivo as compared with more traditional vaccination methods. Compositions, methods of use and methods for preparation of these DCs and Mphs with cancer cells are also disclosed herein.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: June 1, 2021
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Gavreel Kalantarov, Ilya Trakht
  • Patent number: 11020455
    Abstract: There is provided a Colony Stimulating Factor (CSF) as an active ingredient for use in the treatment of colon or pancreatic cancer through an increase in neutrophilia, wherein the Colony Stimulating Factor is selected from the group consisting of Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) and Granulocyte Colony Stimulating Factor (G-CSF). The new use for these two recombinant proteins represents a new treatment option for two of the most frequent forms of cancer.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: June 1, 2021
    Assignee: ENDOR TECHNOLOGIES, S.L
    Inventors: Laura Vivero Sánchez, Luciano Sobrevals Amieva, Rafael Miñana Prieto, Judith Sendra Cuadal, Joaquín Querol Sastre
  • Patent number: 11020495
    Abstract: Genetically modified non-human animals and methods and compositions for making and using them are provided, wherein the genetic modification comprises a deletion of the endogenous low affinity Fc?R locus, and wherein the mouse is capable of expressing a functional FcR?-chain. Genetically modified mice are described, including mice that express low affinity human Fc?R genes from the endogenous Fc?R locus, and wherein the mice comprise a functional FcR?-chain. Genetically modified mice that express up to five low affinity human Fc?R genes on accessory cells of the host immune system are provided.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: June 1, 2021
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Lynn MacDonald, Naxin Tu, Cagan Gurer, Sean Stevens, Andrew J. Murphy
  • Patent number: 11021519
    Abstract: Methods and compositions are provided for intravitreally delivering a polynucleotide to cone photoreceptors. Aspects of the methods include injecting a recombinant adeno-associated virus comprising a polynucleotide of interest into the vitreous of the eye. These methods and compositions find particular use in treating ocular disorders associated with cone dysfunction and/or death.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: June 1, 2021
    Assignees: Adverum Biotechnologies, Inc., University of Washington
    Inventors: Thomas W. Chalberg, Jr., Jay Neitz, Maureen Neitz
  • Patent number: 11013755
    Abstract: The invention relates to inhibitors of microRNAs 19a and 19b and their use for treating or preventing conditions or diseases which are associated with bone loss, in particular osteoporosis and osteogenesis imperfect (01). The inhibitors are also useful for inducing an anabolic effect in bone, either alone or when administered in combination with parathyroid hormone or a recombinant fragment thereof. The invention further relates to inhibitors of microRNAs 19a and 19b and their use for treating or preventing conditions or diseases which are associated with reduced muscle function, in particular muscle degeneration and muscle atrophy. The inhibitors are also useful for stabilizing and/or strengthening muscle function. In addition, inhibitors of microRNAs 19a and 19b can be used for treating or preventing cancer-related bone destruction or bone metastasis.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: May 25, 2021
    Assignee: UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF
    Inventors: Eric Hesse, Hanna Taipaleenmäki, Hiroaki Saito
  • Patent number: 11015199
    Abstract: The invention relates to a genetically transformed or transfected bacterial cell chromosome wherein said cell is made to express interfering RNA (siRNA) active against at least one gene encoding a cancer promoting or sustaining protein such as an oncogene, a chemo-resistant gene or a metabolic gene; siRNA cassette encoding at least one siRNA active against said gene; a bacterial cell with said siRNA cassette integrated within the bacterial chromosome; a method of treating cancer, particularly but not exclusively prostate, breast or colorectal cancer, employing the use of said bacterial cell with a chromosomally integrated siRNA cassette; and use of said bacterial cell with a chromosomally integrated siRNA cassette to treat said cancer.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: May 25, 2021
    Assignee: Swansea University
    Inventor: Paul Dyson
  • Patent number: 11007374
    Abstract: Various systems and methods are implemented for controlling stimulus of a cell. One such method is implemented for optical stimulation of a cell expressing an NpHR ion pump. The method includes the step of providing a sequence of stimuli to the cell. Each stimulus increases the probability of depolarization events occurring in the cell. Light is provided to the cell to activate the expressed NpHR ion pump, thereby decreasing the probability of depolarization events occurring in the cell.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: May 18, 2021
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Karl Deisseroth, Feng Zhang, Edward Boyden
  • Patent number: 11000590
    Abstract: The present disclosure relates to a composition for transduction of a virus in a cell by using a crosslinked product of PEGylated magnetic nanoparticles and catechol grafted poly-L-lysine by application of an external magnetic field. When the composition is used, a virus may be delivered into cells more rapidly and efficiently than in intracellular uptake of a virus by CAR-mediated endocytosis.
    Type: Grant
    Filed: June 5, 2019
    Date of Patent: May 11, 2021
    Assignee: GENEMEDICINE CO., LTD.
    Inventors: Chae Ok Yun, Joung-Woo Choi
  • Patent number: 11001859
    Abstract: The present invention is directed to recombinantly-modified adeno-associated virus (AAV) helper vectors that are capable of increasing the packaging efficiency of recombinantly-modified adeno-associated virus (rAAV) and their use to improve the packaging efficiency of such rAAV. The present invention is particularly directed to recombinantly-modified adeno-associated virus (AAV) helper vectors that have been further modified to replace (or augment) the P5 and/or P40 promoter sequences that are natively associated with the Rep proteins encoded by such rAAV with AAV P5 and/or P40 promoters that are associated with the Rep proteins of an rAAV of different serotype. The use of such substitute or additional promoter sequences causes increased production of recombinantly-modified adeno-associated virus.
    Type: Grant
    Filed: December 6, 2019
    Date of Patent: May 11, 2021
    Assignee: Vigene Biosciences, Inc.
    Inventor: Qizhao Wang
  • Patent number: 11000559
    Abstract: The present disclosure provides a replication competent oncolytic adenovirus with selectivity for cancer cells, wherein the adenovirus comprises a transgene under the control of a promoter endogenous to the virus, wherein the transgene comprises a DNA sequence encoding a B7 protein or an active fragment thereof, compositions comprising same, methods of generating the viruses, and use of the viruses and compositions in treatment, particularly in the treatment of cancer.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: May 11, 2021
    Assignee: PsiOxus Therapeutics Limited
    Inventors: Brian Robert Champion, Alice Claire Noel Bromley
  • Patent number: 10994009
    Abstract: A method of treating pulmonary metastasis of osteosarcoma cells (pOSs) in a subject in need thereof includes administering to the subject a therapeutically effective amount of an agent that interferes with VCAM-1/?4?1 signaling between pOSs expressing VCAM-1 and pulmonary macrophages (MACs) expressing ?4?1.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: May 4, 2021
    Assignee: CASE WESTERN RESERVE UNIVERSITY
    Inventors: Alex Yee-Chen Huang, Jay T. Myers
  • Patent number: 10993972
    Abstract: Provided are: a transformation plasmid for transforming anaerobes and enabling highly efficient and stable secretory expression of a target protein; a gene delivery carrier formed from said anaerobes transformed by said plasmid; a pharmaceutical composition including said gene delivery carrier; and a method for diagnosing or treating an ischemic disease utilizing these. Also provided are: a novel secretory signal; a transformation plasmid including said secretory signal; a gene delivery carrier formed from anaerobes transformed by said plasmid; a pharmaceutical composition including said gene delivery carrier; and a method for diagnosing or treating an ischemic disease utilizing these.
    Type: Grant
    Filed: January 18, 2016
    Date of Patent: May 4, 2021
    Assignees: Shinshu University, Anaeropharma Science, Inc.
    Inventors: Yuko Wada, Yuko Shimatani, Takashi Yano, Takeshi Masaki
  • Patent number: 10980859
    Abstract: The invention provides an in vivo individualized systemic immunotherapeutic method and device. The method includes, in a non-sequential manner: (1) increasing release amount of tumor antigens at a tumor site; (2) at the tumor site, increasing level of proteins capable of adhering to and/or wrapping the tumor antigens; (3) at the tumor site, increasing level of dedicated antigen-presenting cells involved in immunity, and establishing, between the dedicated antigen-presenting cells and immune effector cells, a close connection capable of activating the immune effector cells; and (4) at the tumor site, increasing level and improving function of the immune effector cells. The steps (1)-(4) each reaches a maximum value at a respective time which overlaps with each other maximally, as well as at a respective site which overlaps with each other maximally. The invention combines oncolytic therapy and immunotherapy, in individualized systemic immunotherapy, and provides significantly improved therapeutic effect.
    Type: Grant
    Filed: March 2, 2016
    Date of Patent: April 20, 2021
    Assignee: Hangzhou Converd Co., Ltd.
    Inventors: Fang Hu, Ronghua Zhao, Siyi Chen, Bo Wu, Huiqun Xia, Yanjun Zheng
  • Patent number: 10982228
    Abstract: Provided herein are improved rAAV (e.g., rAAV2, rAAVrh8R, etc.) for enhanced gene therapy of ocular disorders or CNS disorders wherein the rAAV comprise one or more substitutions of amino acids that interact with heparan sulfate proteoglycan. The invention provides methods for improved transduction of retinal cells and methods for treating ocular diseases with improved compositions of rAAV particles. Further provided herein are improved recombinant adeno-associated virus (rAAV) (e.g., rAAV2, rAAVrh8R, etc.) for enhanced gene therapy of disorders of the CNS. The invention provides methods for delivering the rAAV to the CNS, methods for treating disorders of the CNS with improved compositions of rAAV particles, and kits for delivering the rAAV to the CNS and/or treating a CNS disorder.
    Type: Grant
    Filed: May 2, 2015
    Date of Patent: April 20, 2021
    Assignee: Genzyme Corporation
    Inventors: Abraham Scaria, Jennifer Sullivan
  • Patent number: 10975374
    Abstract: A composition for treating cancer is disclosed. The composition includes a lentiviral particle and an aminobisphosphonate drug. The lentiviral particle is capable of infecting a target cell, such as a cancer cell, and includes an envelope protein optimized for targeting such target cell and a viral vector. The viral vector includes a small RNA optimized to target an FDPS mRNA sequence. The aminobisphosphonate drug includes zoledronic acid.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: April 13, 2021
    Assignee: American Gene Technologies International Inc.
    Inventors: Tyler Lahusen, Mei-Ling Liou, Lingzhi Xiao, Haishan Li, Charles David Pauza
  • Patent number: 10975079
    Abstract: The present invention relates to 5-amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives of the general formula (I) or pharmaceutically acceptable salts or propharmacons thereof for use as BCRP inhibitors, wherein at least one hydrogen atom in at least one of the phenyl groups A and B is substituted by a substituent RH, which has a Hammett constant ?p greater than 0.23. For corresponding compounds, surprisingly a particularly high inhibitory activity against BCRP has been discovered which can be exploited for suppressing the multidrug resistance modulator BCRP, thus providing an improvement in efficacy of BCRP affected drugs. This has useful implications for cancer and HIV treatment.
    Type: Grant
    Filed: February 24, 2016
    Date of Patent: April 13, 2021
    Assignee: Scandion Oncology A/S
    Inventors: Steffen Rump, Henning Weigt
  • Patent number: 10973928
    Abstract: Sequences of novel adeno-associated virus capsids and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production of rAAV particles. AAV-mediated delivery of therapeutic and immunogenic genes using the vectors of the invention is also provided.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: April 13, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: James M. Wilson, Guangping Gao, Mauricio R. Alvira, Luc H. Vandenberghe
  • Patent number: 10968454
    Abstract: Various aspects and embodiments of the present disclosure are directed to methods and compositions for functionalizing endogenous bacteria in vivo. The methods include delivering to endogenous bacterial cells a recombinant bacteriophage or phagemid that is engineered to contain at least one genetic circuit.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: April 6, 2021
    Assignees: Massachusetts Institute of Technology, Trustees of Boston University
    Inventors: Timothy Kuan-Ta Lu, Robert James Citorik, James Collins, Russell-John Krom
  • Patent number: 10953108
    Abstract: The invention includes compositions and methods of generating a chimpanzee-derived adenovirus AdC6 or AdC7 vector vaccine comprising a deletion of E1, a deletion of E3 ORF3, ORF4, ORF5, ORF6, and ORF7 and a sequence encoding HIV protein gp140, gp160 or Gag, methods of treating and/or preventing or immunizing against HIV and methods of inducing an effector T cell, memory T cell and B cell immune response in a mammal administered the composition produced thereby. Furthermore, the invention encompasses a pharmaceutical composition for vaccinating a mammal as well as a protein expression system.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: March 23, 2021
    Assignee: The Wistar Institute of Anatomy and Biology
    Inventors: Hildegund C. J. Ertl, Xiang Yang Zhou
  • Patent number: 10954274
    Abstract: A new species of circovirus, porcine circovirus type 3 (PCV3), was identified from sows with clinical symptoms normally associated with porcine circovirus type 2 (PCV2) infection and in aborted fetuses. Molecular and serological analyses suggest PCV3 commonly circulates in U.S. swine. The present disclosure provides immunological compositions and methods related to the production and administration of such compositions.
    Type: Grant
    Filed: October 11, 2019
    Date of Patent: March 23, 2021
    Assignee: Kansas State University Research Foundation
    Inventor: Ben Hause
  • Patent number: 10947500
    Abstract: In certain aspects the present invention provides engineered neural cells, neural stem cells, or neural progenitor cells that contain a nucleotide sequence that encodes an adenovirus E40RF1 polypeptide and/or that contain an adenovirus E40RF1 polypeptide. The present invention also provides methods of making and using such engineered cells and compositions comprising such engineered cells.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: March 16, 2021
    Inventors: Liang Qiang, Daniel Joseph Nolan, Claude Geoffrey Davis
  • Patent number: 10947283
    Abstract: The present disclosure provides immunogenic compositions, such as vaccines, including DNA vaccines, and uses thereof, e.g., which include an annexin core domain to mediate efficient antigen delivery and antigen presentation in order to induce an antigen-specific immune response and/or to treat or prevent infectious diseases and/or cancer.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: March 16, 2021
    Assignee: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS
    Inventors: Fatmire Bujupi, Peter Krammer, Heiko Weyd
  • Patent number: 10942189
    Abstract: The present disclosure teaches an assay to determine the likelihood of a successful implantation of an embryo into a female subject leading to a pregnancy. Enabled herein is an improved assisted reproduction technology protocol based on a prognostic evaluation of pregnancy outcomes. Taught herein is a composition comprising reagents required for the prognostic evaluation. Taught herein are assays comprising determination of levels of the biomarkers IL-8, G-CSF and/or VEGFA in a biological fluid sample taken before embryo implantation.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: March 9, 2021
    Assignee: Hudson Institute of Medical Research
    Inventors: Lois Salamonsen, Tracey Edgell, Natalie Hannan, Luk Rombauts
  • Patent number: 10941387
    Abstract: The present invention relates to the field of insect pests control, using methods and compositions which comprise of alpha-amylase analogous mutant inhibitors (?AIs). More specifically, the invention provides new ?AIs analogous mutant molecules for controlling insect pests, in particular boll weevils (Anthonomus grandis), partially or totally presenting reduction of the amylolytic activity of the digestive enzymes in the intestinal lumen of the insect. Other aspects of the invention include gene constructs containing the nucleic acid molecules that code for the alpha-amylase inhibitors, heterologous expression methods of the new molecules in the active form, and the use of these molecules for controlling insect pests. The invention also provides analogous synthetic genes optimized for their transformation and expression in plants.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: March 9, 2021
    Assignee: EMPRESA BRASILEIRA DE PESQUISA AGROPECUÁRIA—EMBRAPA
    Inventors: Maria Fatima Grossi De Sa, Maria Cristina Mattar Da Silva, Rafael Perseguini Del Sarto, Thales Lima Rocha
  • Patent number: 10940199
    Abstract: Disclosed are methods, kits, polypeptides, and pharmaceutical compositions for inducing an immune response in a subject, which may include a T-cell mediated immune response. The methods comprise administering to the subject, or to explanted cells of the subject, a pharmaceutical composition comprising an effective amount of versikine or a variant of versikine that induces the T-cell mediated immune response. The methods, kits, polypeptides, and pharmaceutical compositions may be used, in particular, to treat a subject having a cell proliferative disease or disorder.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: March 9, 2021
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Fotios Asimakopoulos, Chelsea Hope
  • Patent number: 10934521
    Abstract: The present invention relates to genetically modified microorganisms comprising one or more heterologous nucleic acid molecules together encoding at least three different proteins, each protein comprising an enzymatic domain and a bacterial microcompartment-targeting signal polypeptide, wherein said enzymatic domains each catalyse a different substrate to product conversion in the same metabolic pathway, and wherein said microorganisms are essentially free of bacterial microcompartments (BMCs); and to cell free systems comprising aggregates comprising at least three different proteins, each protein comprising an enzymatic domain and a bacterial microcompartment-targeting signal polypeptide, wherein said enzymatic domains each catalyse a different substrate to product conversion in the same metabolic pathway, and wherein said system does not comprise bacterial microcompartments; and to methods for the production of said microorganisms and cell free systems and their use in methods of producing a product of int
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: March 2, 2021
    Assignee: UNIVERSITY OF KENT
    Inventors: Matthew John Lee, Stefanie Frank, Martin James Warren
  • Patent number: 10920244
    Abstract: An artificial AAV capsid comprising a heterologous conducting airway targeting sequence is provided. The artificial AAV is useful as a targeting moiety, for delivery of heterologous molecules which are associated therewith. The artificial AAV is also useful in the generation of AAV vectors having the artificial capsid. Also described are methods of modifying the native tropism and transduction efficiency of vectors by improving and/or ablating their ability to transduce conducting airway cells. Methods of targeting conducting airway cells and delivering therapeutic and other molecules thereto are also provided.
    Type: Grant
    Filed: April 29, 2010
    Date of Patent: February 16, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Christie L Bell, James M Wilson
  • Patent number: 10918677
    Abstract: The present invention provides attenuated or inactivated pathogenic bacteria having anti-cancer properties, compositions comprising the bacteria, and use thereof for treating cancers of the urogenital system.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: February 16, 2021
    Assignees: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
    Inventors: Ofer Mandelboim, Gilad Benjamin Bachrach, Chamutal Gur, Vladimir Yutkin
  • Patent number: 10913799
    Abstract: Antibodies and methods of using these antibodies are provided which bind human and mouse receptor activator of nuclear factor kappa-B ligand, said antibodies are useful as agents for treating conditions associated with bone-related disorders or skeletal abnormalities caused by cancer.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: February 9, 2021
    Assignee: Eli Lilly and Company
    Inventors: Andrew Ihor Korytko, Victor H Obungu
  • Patent number: 10898590
    Abstract: A method for delivery of a therapeutic agent to a nervous tissue. In particular, a method of delivering a therapeutic agent to a nervous tissue protected by the brain-blood barrier or meninges is disclosed. The method for delivery allows delivery of a therapeutic agent to a nervous tissue with high efficiency. In addition, the delivery method of a therapeutic agent to a nervous tissue is safe since it has lower side effects such as nervous damage than a method of administering a therapeutic agent directly to a nervous tissue.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: January 26, 2021
    Assignee: KOLON LIFE SCIENCE, INC.
    Inventors: Sujeong Kim, Heonsik Choi, Kyoungbaek Choi, Minjung Kim, Yejin Kwon, Hyeonyoul Lee, Minju Kim, Daewook Kim, Jangjoon Park, Yeomoon Sim
  • Patent number: 10898569
    Abstract: The present invention relates to compositions, immunogenic or vaccine compositions and pharmaceutical compositions for the prevention or treatment of peanut allergy in humans. Furthermore, the invention provides methods for preventing or treating of peanut allergy in humans.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: January 26, 2021
    Assignee: ALLERGY THERAPEUTICS (UK) LIMITED
    Inventors: Matthias F. Kramer, Andris Zeltins, Murray A. Skinner, Matthew D. Heath
  • Patent number: 10888628
    Abstract: Compositions and regimens useful in treating hemophilia A are provided. The compositions include recombinant adeno-associated virus (rAAV) with a transthyretin enhancer and promoter driving expression of a human Factor VIII.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: January 12, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Lili Wang, James M. Wilson, Jenny Agnes Sidrane
  • Patent number: 10888594
    Abstract: The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: January 12, 2021
    Assignees: National University Corporation Tottori University, Astellas Pharma Inc.
    Inventors: Shinsuke Nakao, Tatsuya Kawase, Takafumi Nakamura
  • Patent number: 10888227
    Abstract: Apparatus and methods are presented herein that permit real-time, accurate detection of residual tumor in the operating room. The Raman-based wide-field imaging apparatus and methods described herein permit real-time imaging of tumor-targeted R-MR nanoparticles over a wide field. Apparatus and methods are presented herein for operating a Raman-based resection system.
    Type: Grant
    Filed: August 20, 2014
    Date of Patent: January 12, 2021
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Moritz Kircher, Ricardo Toledo-Crow
  • Patent number: 10883117
    Abstract: The present disclosure provides recombinant adeno-associated virus (rAAV) virions comprising a variant AAV capsid protein, e.g., an AAV capsid protein derived from an ancestral AAV capsid protein amino acid sequence. An rAAV virion of the present disclosure can exhibit greater infectivity of a target cell. The present disclosure also provides methods of delivering a gene product to a target cell in an individual by administering to the individual an rAAV of the present disclosure. The present disclosure also provides methods of generating rAAV virions that have a variant AAV capsid protein derived from an ancestral AAV capsid protein amino acid sequence.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: January 5, 2021
    Assignee: The Regents of the University of California
    Inventors: David S. Ojala, Jorge Santiago-Ortiz, Oscar Westesson, David V. Schaffer, Ian H. Holmes, John Weinstein
  • Patent number: 10876104
    Abstract: The present invention provides, among other things, methods of purifying messenger RNA (mRNA) including the steps of subjecting an impure preparation comprising in vitro synthesized mRNA to a denaturing condition, and purifying the mRNA from the impure preparation from step (a) by tangential flow filtration, wherein the mRNA purified from step (b) substantially free of prematurely aborted RNA sequences and/or enzyme reagents used in in vitro synthesis.
    Type: Grant
    Filed: March 26, 2018
    Date of Patent: December 29, 2020
    Assignee: Translate Bio, Inc.
    Inventors: Michael Heartlein, Frank DeRosa, Anusha Dias, Shrirang Karve
  • Patent number: 10857210
    Abstract: Compositions and methods to promote wound healing are described. The compositions and methods up-regulate X-box binding protein 1 (XBP1) and/or inositol-requiring enzyme-1 (IRE-1). In various embodiments, the compositions and methods can be used to promote wound healing in diabetic subjects.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: December 8, 2020
    Assignee: Wayne State University
    Inventors: Kezhong Zhang, Jiemei Wang
  • Patent number: 10849946
    Abstract: The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: December 1, 2020
    Assignees: National University Corporation Tottori University, Astellas Pharma Inc.
    Inventors: Shinsuke Nakao, Tatsuya Kawase, Takafumi Nakamura
  • Patent number: 10842835
    Abstract: Methods utilizing vaccinia virus with mutations in E3L to infect and cause lysis of cancer cells with less than normal protein levels of RIP3 and/or DAI. Further, the disclosed vaccinia viruses with mutations in E3L cannot replicate well in cells with normal expression or upregulation of RIP3, DAI, and/or MLKL.
    Type: Grant
    Filed: May 25, 2017
    Date of Patent: November 24, 2020
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Bertram Jacobs, Heather Koehler, William Arndt, Karen Kibler, Kelly Trainor, Chandra Mitnik, Jeffrey Langland
  • Patent number: 10842790
    Abstract: An object of the present invention is to provide an immunopotentiating agent for reducing Tregs (in particular, effector Tregs) and potentiating tumor immunity or infection immunity. Imatinib and/or a salt thereof has the action of reducing Tregs (in particular, effector Tregs) and potentiating tumor immunity or infection immunity, and can be used as an active ingredient for the immunopotentiating agent.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: November 24, 2020
    Assignee: OSAKA UNIVERSITY
    Inventors: Hiroyoshi Nishikawa, Shimon Sakaguchi, Atsushi Tanaka
  • Patent number: 10836800
    Abstract: Fusion proteins containing a targeting sequence, an exosporium protein, or an exosporium protein fragment that targets the fusion protein to the exosporium of a Bacillus cereus family member are provided. Recombinant Bacillus cereus family members expressing such fusion proteins are also provided. Genetically inactivated Bacillus cereus family members and recombinant Bacillus cereus family members that overexpress exosporium proteins are also provided. Seeds coated with the recombinant Bacillus cereus family members and methods for using the recombinant Bacillus cereus family members (e.g., for stimulating plant growth) are also provided. Various modifications of the recombinant Bacillus cereus family members that express the fusion proteins are further provided. Fusion proteins comprising a spore coat protein and a protein or peptide of interest, recombinant bacteria that express such fusion proteins, seeds coated with such recombinant bacteria, and methods for using such recombinant bacteria (e.g.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: November 17, 2020
    Assignee: Spogen Biotech Inc.
    Inventors: Brian Thompson, Ashley Siegel
  • Patent number: 10835561
    Abstract: Bacillus strains, compositions and methods are disclosed for reducing growth of microorganisms in a feed. Bacillus strains, compositions and methods are disclosed for providing beneficial effects to animals, including but not limited to increasing performance of the animal.
    Type: Grant
    Filed: May 25, 2017
    Date of Patent: November 17, 2020
    Assignee: Church & Dwight Co., Inc.
    Inventors: Thomas Rehberger, John O'Neill, Alexandra Smith, Mari Ellen Davis, Jesse Thompson, Jennifer Schissel
  • Patent number: 10837028
    Abstract: The disclosure relates, in some aspects, to compositions and methods for treatment of diseases associated with aberrant lysosomal function, for example Parkinson's disease and Gaucher disease. In some embodiments, the disclosure provides expression constructs comprising a transgene encoding beta-Glucocerebrosidase (GBA) or a portion thereof, Lysosomal Membrane Protein 2 (LIMP2), Prosaposin, or any combination of the foregoing. In some embodiments, the disclosure provides methods of Parkinson's disease by administering such expression constructs to a subject in need thereof.
    Type: Grant
    Filed: November 20, 2019
    Date of Patent: November 17, 2020
    Assignee: Prevail Therapeutics, Inc.
    Inventors: Asa Abeliovich, Laura Heckman, Herve Rhinn
  • Patent number: 10835600
    Abstract: The present invention relates to the use of a composition in a method of reducing the allergenicity of a cat. Moreover, the present invention relates to the use of a composition in a method of reducing the allergenicity of a cat for a human exposed to the cat. Furthermore, the present invention relates to compositions comprising a virus-like particle (VLP) and at least one Fel d1 protein. The compositions of the invention induce efficient immune responses, in particular antibody responses, in cats and are useful for the treatment and/or prevention of cat allergy.
    Type: Grant
    Filed: September 7, 2016
    Date of Patent: November 17, 2020
    Assignee: UNIVERSITÄT ZÜRICH
    Inventors: Martin Bachmann, Gary Jennings, Thomas Kündig, Gabriela Senti, Franziska Zabel
  • Patent number: 10829529
    Abstract: The present disclosure provides recombinant nucleic acids comprising one or more polynucleotides encoding a cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide (e.g., a human CFTR polypeptide); viruses comprising the recombinant nucleic acids; compositions and formulations comprising the recombinant nucleic acids and/or viruses; methods of their use (e.g., for the treatment of a chronic lung disease, such as cystic fibrosis); and articles of manufacture or kits thereof.
    Type: Grant
    Filed: February 7, 2020
    Date of Patent: November 10, 2020
    Assignee: KRYSTAL BIOTECH, INC.
    Inventors: Trevor Parry, Suma Krishnan, Pooja Agarwal
  • Patent number: 10830639
    Abstract: Certain examples disclose systems and methods for imaging a target. An example method includes: a) activating a subset of light-emitting molecules in a wide field area of a target using an excitation light; b) capturing one or more images of the light emitted from the subset of the molecules illuminated with the excitation light; c) localizing one or more activated light emitting molecules using one or more single molecule microscopic methods to obtain localization information; d) simultaneously capturing spectral information for the same localized activated light emitting molecules using one or more spectroscopic methods; e) resolving one or more non-diffraction limited images of the area of the target using a combination of the localization and spectral information for the localized activated light emitting molecules; and f) displaying the one or more non-diffraction limited images.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: November 10, 2020
    Assignee: Northwestern University
    Inventors: Ben Urban, Hao F. Zhang, Cheng Sun, Biqin Dong
  • Patent number: 10821177
    Abstract: This invention relates to methods of inducing differential stress resistance in a subject with cancer by starving the subject for a short term, administering a cell growth inhibitor to the subject, or reducing the caloric or glucose intake by the subject. The induced differential stress resistance results in improved resistance to cytotoxicity in normal cells, which, in turn, reduces cytotoxic side-effects due to chemotherapy, as well as improved effectiveness of chemotherapeutic agents.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: November 3, 2020
    Assignee: UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventor: Valter Longo
  • Patent number: 10822412
    Abstract: Chimeric antigen receptors containing CD19/CD22 or CD22/CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: November 3, 2020
    Assignee: LENTIGEN TECHNOLOGY, INC.
    Inventors: Dina Schneider, Rimas J. Orentas, Boro Dropulic, Peirong Hu
  • Patent number: RE48345
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a Hepatitis B Virus gene. The invention also relates to a pharmaceutical composition comprising the dsRNA or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Hepatitis B Virus infection using said pharmaceutical composition; and methods for inhibiting the expression of a Hepatitis B Virus gene in a cell.
    Type: Grant
    Filed: August 19, 2016
    Date of Patent: December 8, 2020
    Assignee: Arrowhead Pharmaceuticals Inc.
    Inventors: Daniel J. Chin, Jochen Deckert, Markus Hossbach, Matthias John